A meta-analysis of nine observational studies, involving 338 KTRs with a median follow-up time of 12 months, found that treatment with GLP-1 RAs was associated with a decrease in proteinuria but did not significantly alter eGFR levels [22]
In addition, several clinical trials are ongoing to assess therapeutic interventions targeting gut hormones and their receptors in metabolic diseases
actual results vary depending on dosage, duration of treatment, baseline levels, and individual factors like diet, exercise, weight loss, and genetics
Weight loss medication is not necessarily for everyone
Funding This work was supported by National Science Centre in Poland, grant number 2014/15/B/NZ7/00893